Kiromic BioPharma, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

HOUSTON–(BUSINESS WIRE)–$KRBP #KRBP—Kiromic BioPharma, Inc. (Nasdaq: KRBP) is an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics.

Today, the Company announced an interview with the CEO, Dr. Maurizio Chiriva-Internati, which will air on The RedChip Money Report on the Bloomberg Network.

The CEO Interview will air on Bloomberg Television at the time slot below:

The CEO interview will cover these subjects:

— IND filing timelines

— IND expanded indications

— GMP manufacturing updates

The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. local time, reaching up to 73 million homes.

To view the interview segment, please visit https://youtu.be/Wg8Z6Ixmdi4.

“The RedChip Money Report” delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

About Kiromic

Kiromic BioPharma, Inc. is an immuno-oncology biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline. The pipeline development is leveraged through the Company’s proprietary target discovery engine called “DIAMOND.” Kiromic’s DIAMOND is essentially big data science meeting target identification, dramatically compressing the man-years and the millions of drug development dollars needed to develop a live drug. The Company’s headquarters are in Houston, TX adjacent to the world’s largest medical center and the MD Anderson Cancer Center. For more information, please visit www.kiromic.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about our intentions, projections, assessments, or expectations regarding items such as the following:

— our goals and strategies

— research, development, and regulatory activities

— FDA authorization timeline for clinical trial initiation

— clinical trial enrollment or participation by clinical sites

— facility manufacturing capabilities for clinical trial support

— expectations related to gamma delta CAR therapy

— performance and success of clinical trials

— our future business development, financial condition, and results of operations

— expected changes in our revenue, costs, or expenditures

— growth of and competition trends in our industry

— our expectations regarding demand for, and market acceptance of, our products

— our expectations regarding our relationships with investors, institutional funding partners and other parties we collaborate with

— fluctuations in general economic and business conditions in the markets in which we operate; including those fluctuations caused by COVID-19

— relevant government policies and regulations relating to our industry.

In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading “Risk Factors” included in our Registration Statement on Form S-1 (file no. 333-238153), originally filed with the Securities and Exchange Commission (SEC) on May 11, 2020, as amended, and elsewhere in this press release. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason. You are advised, however, to review any further disclosures we make on related subjects in our Forms 10-Q, 8-K and other reports filed with the SEC.

Contacts

Kiromic contact:

Tony Tontat

Chief Financial Officer

(844) 539 – 2873

ttontat@kiromic.com

Investor Relations:

Dave Gentry

RedChip Companies Inc.

Dave@redchip.com
407-491-4498 or 1-800-RED-CHIP (733-2447)